Research on lung cancer detection and treatment. Covers microbial predictors of immunotherapy, MRI detection, microplastics, and RAS-mutant drugs.
A new trial found that video-assisted thoracic surgery (VATS) significantly reduces in-hospital complications and shortens hospital stays compared to open surgery for early-stage lung cancer patients. VATS, a minimally invasive technique, showed improved outcomes without compromising oncologic results.
A European lung cancer screening model outperformed a US model in detecting cancers, with 99% of cancers found using the European method compared to 77%. The study found that the model detected more cancers among high-risk patients and had a higher accuracy rate.
A Phase 1 study demonstrated early promising antitumor activity and few adverse side effects in patients with advanced non-small cell lung cancer harboring KRAS G12C mutation. The therapy, AMG 510, showed encouraging anti-tumor activity with no dose-limiting toxicities or adverse events leading to discontinuation.
Research presented at the IASLC 2019 World Conference on Lung Cancer found that combining nivolumab with ipilimumab showed improved efficacy in patients with advanced non-small cell lung cancer (NSCLC), particularly those with high TMB or higher tumor PD-L1 expression. The safety profile of this combination therapy was also consistent ...
Researchers found no significant correlation between tumor mutational burden and response rates, progression-free survival, or overall survival in patients treated with pembrolizumab plus carboplatin and pemetrexed. High objective response rates were observed in both TMB low and high subgroups.
The MYSTIC trial found that patients with STK11 or KEAP1 mutations had poorer outcomes to anti-PD-L1 and anti-CTLA-4 immunotherapies compared to those without these mutations. ARID1A mutations were associated with improved survival in the durvalumab + tremelimumab arm.
Researchers studied the relationship between tumor mutational burden and response to immunotherapy with pembrolizumab. The study found that high or low TMB levels did not significantly impact overall survival, progression-free survival, or objective response rates for patients with metastatic nonsquamous non-small cell lung cancer.
The MYSTIC trial found that patients with STK11 or KEAP1 gene mutations in metastatic non-small cell lung cancer experienced poorer overall survival compared to those without these mutations. Additionally, patients with ARID1A mutations in the durvalumab + tremelimumab arm had longer median overall survival rates.
The bioMILD trial demonstrated that combining low-dose CT screening with a microRNA blood test reduces lung cancer mortality and incidence in high-risk individuals. The study found that participants with positive LDCT and/or miRNA at baseline had a significantly higher lung cancer incidence and overall mortality.
Cancer patients who continue smoking after diagnosis have a higher mortality rate and increased risk for second cancer development. The IASLC Declaration recommends screening all cancer patients for tobacco use and advising on tobacco cessation.
Researchers at H. Lee Moffitt Cancer Center describe a promising new treatment combination for patients with non-small cell lung cancer, showing preliminary efficacy and improved tolerance compared to standard treatments.
Researchers found a gene mutation in nearly half of dogs with lung cancer that could be treated with the same drug used for human breast cancer. A clinical trial is planned for dogs with naturally occurring lung cancer and the HER2 mutation.
Researchers at Moffitt Cancer Center have discovered a new treatment approach that may help nearly a third of lung cancer patients with KRAS mutations. The combination therapy targets the MEK kinase and enhances anti-tumor immunity through cytokines TNFα and IFNγ.
Researchers found that combining therapies reduced tumor relapse and side effects in mouse models of kinase mutated breast cancer. The study suggests using two therapies together, rather than one after the other, to improve treatment outcomes.
Researchers combine checkpoint blockade therapy with stem cell transplantation to boost efficacy in non-Hodgkin's lymphomas and melanoma. The approach increases cancer-killing immune response tenfold, allowing it to be effective for previously treatment-resistant cancers.
Researchers at Mayo Clinic have identified two distinct pathways for lung adenocarcinoma development, which can inform treatment strategies and predict patient response. The study's findings suggest that targeting specific pathways may provide alternative treatment options for patients with limited response to traditional therapies.
Scientists have developed a highly sensitive 'sniff-cam' that can detect low levels of disease biomarkers in breath, including diabetes, lung cancer, and Parkinson's disease. The device uses an ultraviolet ring light, filters, and a camera to measure volatile organic compounds (VOCs) in the breath.
Retinitis pigmentosa (RP) is caused by the starvation of photoreceptors due to disrupted glucose transport. Research led by UofL's Douglas C. Dean and Wei Wang found similar metabolic changes in lung cancer.
Researchers have discovered that two enzymes, SIK1 and SIK3, play a critical role in driving tumor growth in non-small-cell lung cancer by promoting inflammation. The findings highlight a potential new target for therapies and could lead to improved treatment options for patients with this deadly form of lung cancer.
A new AI tool developed by Dana-Farber Cancer Institute can extract high-value cancer outcomes from unstructured radiology reports with comparable accuracy to human reviewers. The tool, trained on over 14,000 imaging reports, was able to replicate human assessments of disease-free survival and progression-free survival.
A new study published in Science Advances reveals that a cellular switch called CREB plays a key role in directing tumor growth in non-small-cell lung cancer. Researchers found that blocking this switch could have therapeutic benefits for patients with this deadly type of cancer.
A new AI tool, CXR-risk, analyzes chest X-ray images to predict health and mortality, providing independent information that surpasses radiologists' readings. The study found that CXR-risk identified people at high risk for future heart attack, lung cancer, or death with accuracy.
A Northwestern University study found that many deadliest cancers, such as colon, lung, and liver cancer, receive significantly less nonprofit research funding than breast cancer, leukemia, and other well-funded types. This underfunding could impact research, drug development, and FDA approvals for these life-altering diseases.
Radiotherapy patients experiencing hurricane disasters had significantly worse overall survival rates than those completing treatment in normal circumstances. Longer disaster declarations were associated with increasingly worse survival outcomes.
Researchers at Massachusetts General Hospital have identified markers that can distinguish between major subtypes of lung cancer and accurately predict lung cancer stage. The study's findings could help physicians decide whether an individual patient with lung cancer benefits from standard treatment or needs more aggressive therapy.
Researchers found adding pembrolizumab to definitive treatment increased overall average PFS by 19.1 months, compared to 6.6 months in historical averages. The study showed the treatment did not lead to new safety issues or decreased patient quality of life.
Research reveals that epigenetic regulation-mediated metabolic reprogramming enables lung cancer cells to adapt to and resist targeted therapies. BCAT1 upregulation allows for glutathione generation, eliminating oxidative stress and promoting drug resistance.
A follow-up study reaffirms the effectiveness of low-dose computed tomography (LDCT) in reducing lung cancer mortality. The research found that LDCT can prevent lung cancer deaths or at least delay them for more than a decade, with only 303 patients needed to be screened to prevent one death.
The study found that African Americans are excluded from CT scans at a rate of 68%, compared to 32% of whites, due to conservative guidelines. Modifying the minimum smoking history and age thresholds could increase eligibility and reduce disparities.
Researchers have discovered how lung cancer cells metastasize by stabilizing protein BACH1, which stimulates glucose metabolism and boosts cancer cell spreading. The studies published in Cell provide a crucial new piece of the oncological puzzle and offer a potential explanation for the Warburg effect.
A new risk prediction model using clinical and radiological features can stratify individuals with lung nodules as having high or low risk of developing lung cancer. The model, which combines variables such as age, smoking history, and nodule characteristics, showed a sensitivity and specificity of 73% and 81%, respectively.
A new study reveals that high antioxidant levels may accelerate lung cancer spread, contradicting the long-held notion that antioxidants like vitamin E prevent cancer. The research highlights a complex interplay between protein BACH1, NRF2, and heme-driven oxidative stress in facilitating cancer cell migration.
A study suggests that current USPSTF guidelines for African American smokers may lead to fewer screenings due to lower smoking pack-year history. Lowering the pack-year requirement and minimum age criterion could increase eligible African Americans for lung cancer screening.
Scientists discover that UDP-glucose accelerates SNAI1 mRNA decay, impairing lung cancer metastasis. The study also uncovers how UDP-glucose converts to UDP-glucuronic acid, enhancing SNAI1 mRNA stability and promoting tumor cell migration.
Research teams discovered that uridine diphosphate glucose accelerates SNAI1 mRNA decay, impairing lung cancer metastasis. Lower UDP-glucose levels are associated with higher metastasis and recurrence rates in lung cancer.
The Hollings Cancer Center has received a $3 million grant from the National Cancer Institute to continue its research on a novel immunotherapy combination for treating lung cancer. The team, led by Mark Rubinstein and John Wrangle, aims to understand why some patients respond better to this treatment than others.
Researchers have trained beagles to identify lung cancer by scent with 97% accuracy, offering a potential solution for earlier detection. The dogs' abilities may lead to the development of an over-the-counter screening product, similar to a pregnancy test.
Seven early-career scholars are awarded four-year grants to advance their research on reprogramming tumor-associated immune cells, mutant proteins in lung cancer, and treating acute myeloid leukemia.
A study suggests that the current UK legislation favoring cancer patients for early release on compassionate grounds may be discriminatory. The data analysis found that only 48 out of 845 recorded deaths from natural causes in prison were successful, with all six prisoners having cancer.
A retrospective study of 748 NSCLC patients found that the average radiation dose delivered to the heart was associated with an increased risk of major adverse cardiovascular events and death. The team's findings highlight the need for more stringent avoidance of high cardiac radiotherapy doses and collaboration with cardiologists to m...
The combination immunotherapy of nivolumab and ipilimumab met the primary endpoint of the NEOSTAR trial with a 33% overall major pathologic response rate in early-stage lung cancer patients. The treatment was also shown to be effective in reducing tumor viability, with six out of 21 patients achieving a complete pathological response.
A new essay published in Annals of Internal Medicine argues that physicians often have to make difficult decisions when faced with extreme political pressures. The author shares a personal story about caring for a pregnant woman who was forced to carry a baby without a brain, highlighting the need for compassion over 'choice' in patien...
The NRG-LU001 trial showed that metformin was well-tolerated by patients with locally advanced non-small cell lung cancer, but did not improve progression-free survival or overall survival rates. The study found better-than-expected PFS and OS rates in both treatment arms.
A new study presented at ASCO 2019 shows that brigatinib is effective in patients who have received another next-generation ALK inhibitor. The 40-50 percent response rate suggests that brigatinib may be a useful treatment option for these patients. Detailed molecular analyses will help determine the characteristics of patients sensitiv...
A virtual clinical trial using real-world data found entrectinib to be more effective than crizotinib in treating ROS1+ lung cancer. Patients on entrectinib stayed on treatment longer and had a 44% increased chance of cancer recurrence compared to those on crizotinib.
Researchers found that catastrophic genome rearrangements can occur as early as childhood and lead to lung cancer decades later. Gene fusions in non-smokers mostly occur early on, sometimes as early as childhood or adolescence, and are often dormant for several decades before progressing into cancer.
Researchers from Stand Up To Cancer will discuss their work on advancing immunotherapy for pediatric brain tumors, genome-wide cell-free DNA fragmentation profiling for early cancer detection, and personalized consolidation immunotherapy in localized non-small cell lung cancer. The findings highlight promising approaches to screening, ...
A new study from the University of British Columbia found that steroid inhalers can lower lung cancer risk in COPD patients. The research, published in European Respiratory Journal, analyzed data from 39,676 adults with COPD and found a 25-30% reduction in lung cancer risk among those using steroids.
Smokers of unfiltered cigarettes face a significantly higher risk of dying from lung cancer and all causes than those who smoke filtered cigarettes. Researchers found that light or ultralight cigarettes do not offer any lung cancer death reduction benefits, but smokers may be less likely to quit.
A new AI system has been developed that can detect lung cancer with high accuracy, potentially leading to earlier treatment. The system uses deep learning to analyze low-dose chest computed tomography (LDCT) scans and performs better than human radiologists in detecting malignant nodules.
Research at ATS 2019 reveals that smokers with severe lung function limitation are more likely to die from respiratory causes. In contrast, smokers with mild impairment face a higher risk of heart disease and lung cancer.
Scientists have identified a promising compound, PHT-7.3, that shrinks KRAS-driven tumors in mice by targeting the protein's partner, Cnksr1. The study provides a potential treatment for KRAS-positive cancers, which currently have no effective therapy.
New trials suggest whole body MRI can diagnose cancer stage more quickly and accurately than standard imaging for colorectal and non-small cell lung cancers. This reduces treatment decision time from an average of 13 days to 8 days, while costs are lowered by nearly a quarter in some cases.
A large Chinese study found that type 2 diabetes is associated with an elevated risk of 11 types of cancer in men and 13 types of cancer in women. The study, which examined data from over 410,000 adults, revealed significant increases in cancer risk for both men and women with diabetes.
A large study found that adults with high fitness levels had a lower risk of developing lung and colorectal cancer, as well as improved survival rates after diagnosis. Fitness testing is common among adults and may provide valuable information about cancer risk and prognosis.
A new surgical technique using ultrasonic energy to seal pulmonary artery branches has been shown to reduce post-operative bleeding, complications, and pain in patients with lung cancer. The study's results have the potential to make this less invasive procedure more widely available, leading to faster recovery times for thousands of C...
Stand Up To Cancer has awarded five research teams a total of $1.25 million to explore cross-cutting questions in cancer treatment through innovative collaboration. The grant program aims to bring together outstanding researchers from different teams to make use of the extraordinary talent across the SU2C community.
Lung cancer in non-smokers is under-recognized, with an estimated 6,000 deaths per year in the UK. The risk factors include second-hand smoke, occupational carcinogen exposure, and outdoor pollution.
A recent study published in Cancer Epidemiology, Biomarkers & Prevention found that the prevalence of physician-patient discussions about lung cancer screening is very low and declining. In 2017, only 4.3% of the general population discussed lung cancer screening with their doctor, compared to 8.7% among current smokers in 2012.
Researchers identified four genomic subtypes in smokers with precancerous lesions, where immune response is impaired. The study suggests that a therapeutic could reactivate the immune system to intercept lung cancer.